The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

Hypoglycemia is the medical term for abnormally low blood sugar, defined as blood sugar less than 70 mg/dL. By comparison, normal blood sugar levels are between 80 mg/dL and 130 mg/dL, while blood ...

Hypoglycemia is described as blood sugar levels below 70 milligrams per deciliter. It's most commonly seen in people with diabetes, especially type 1 diabetes. Low glucose symptoms include ...

Hypoglycemia is the major barrier to good glycemic control in patients with diabetes mellitus. Furthermore, randomized controlled trials have emphasized the grave risks associated with severe ...

Advertisement management junior Yashika Ramchandani created T100 Pro Bars, power bars geared towards people with diabetes and ...

The following is a summary of “Efficacy and Hypoglycemia Profile of Once-Weekly Insulin Icodec vs. Once-Daily Comparators ...

“Continuous glucose monitors with low-glucose alerts can potentially reduce the risk of hypoglycemia for insulin-treated ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

A thorough review of 21 cases involving acutely ill children associated with these products raises concerns. Researchers ...

The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.